0000000001092787

AUTHOR

H. Myint

showing 1 related works from this author

Incidence, Medical Resource Utilisation and Costs of Hyperuricemia and Tumour Lysis Syndrome in Patients with Acute Leukaemia and Non-Hodgkin's Lymph…

2003

Hyperuricemia (HU) and tumour lysis syndrome (TLS) are complications of acute leukaemia and non-Hodgkin lymphoma (NHL) leading to increased morbidity and mortality. The objective of this study was to define incidence and calculate health care cost associated with HU and TLS. 788 acute leukaemia and NHL patients from Belgium, The Netherlands, Spain and UK were screened retrospectively for HU and TLS. Resource use related to HU and TLS was recorded and costs were calculated applying local unit costs. Results showed that HU occurred in 18.9% of patients, and 27.8% of them fulfilled TLS criteria. The cost of HU without TLS was 672 euros (SE 181), the cost of TLS 7,342 euros (SE 1,412). TLS requ…

Cancer Researchmedicine.medical_specialtyPediatricsmedicine.medical_treatmentHyperuricemiaRenal DialysisRisk FactorsIntensive caremedicineRasburicaseHumansHyperuricemiaChildhealth care economics and organizationsDialysisNetherlandsLeukemiabusiness.industryIncidenceLymphoma Non-HodgkinIncidence (epidemiology)Age FactorsDisease ManagementHealth Care CostsHematologyMiddle Agedmedicine.diseaseUnited KingdomLymphomaSurgeryNon-Hodgkin's lymphomaTumor lysis syndromeOncologySpainAcute DiseaseHealth ResourcesTumor Lysis Syndromebusinessmedicine.drugLeukemia & Lymphoma
researchProduct